Document Detail

A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
MedLine Citation:
PMID:  22759325     Owner:  NLM     Status:  MEDLINE    
BACKGROUND:  Helicobacter pylori eradication has still remained a challenge, especially in case of failure to novel treatments. Therefore, we designed a study to evaluate the effects of a modified bismuth-containing quadruple therapy including a short course of furazolidone on a group of patients whose sequential therapy had been unsuccessful.
MATERIALS AND METHODS:  Thirty-six H. pylori-positive patients who had previously failed a clarithromycin-containing sequential therapy enrolled the study. They received pantoprazole (40 mg-bid), amoxicillin (1 g-bid), and bismuth subcitrate (240 mg-bid) for 2 weeks and furazolidone (200 mg-bid) just during the first week. Eight weeks after treatment, H. pylori eradication was reassessed using C14-urea breath test.
RESULTS: Thirty five patients completed the study. H. pylori eradication rates were 80.6% (95% CI = 67.6-93.5) and 82.9% (95% CI = 70.6-95.2) according to intention-to-treat and per-protocol analyses, respectively. All patients had excellent compliance to treatment, and no one interrupted therapy owing to adverse effects.
CONCLUSION:  Regarding the eradication rate (>80%), low price, and very low adverse effects, a 2-week bismuth-containing quadruple regimen including a short course of furazolidone can be an encouraging regimen for second-line H. pylori eradication in case of sequential therapy failure. Possibly, it can be improved by alterations in dose, dosing intervals, and/or duration.
Hafez Fakheri; Zohreh Bari; Hossein Sardarian
Related Documents :
17983455 - Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.
16432825 - Randomized clinical trial comparing surgery with conservative treatment for uncomplicat...
24286905 - Three-dimensional treatment outcomes in class ii patients treated with the herbst appli...
17826305 - Factors associated with restricted mouth opening and its relationship to health-related...
17451085 - Tamoxifen treatment in a patient with blepharophimosis-ptosis-epicanthus inversus syndr...
23974455 - The correlation between gatifloxacin`s acute adverse reaction and intravenous drip velo...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-09
Journal Detail:
Title:  Helicobacter     Volume:  17     ISSN:  1523-5378     ISO Abbreviation:  Helicobacter     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-04     Completed Date:  2012-11-01     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  9605411     Medline TA:  Helicobacter     Country:  United States    
Other Details:
Languages:  eng     Pagination:  264-8     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use
Amoxicillin / therapeutic use
Anti-Bacterial Agents / therapeutic use*
Bismuth / therapeutic use*
Drug Therapy, Combination
Furazolidone / therapeutic use*
Helicobacter Infections / drug therapy*,  microbiology
Helicobacter pylori / drug effects,  physiology
Middle Aged
Treatment Failure
Treatment Outcome
Young Adult
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Bacterial Agents; 26787-78-0/Amoxicillin; 67-45-8/Furazolidone; 7440-69-9/Bismuth; D8TST4O562/pantoprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics?+?Lac...
Next Document:  Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple T...